Medicare

The American College of Rheumatology is “gravely concerned” about proposed rule changes to the CMS Medicare Physician Fee Schedule and Quality Payment Program, the organization said in a statement.

Mark Cuban Cost Plus Drug Company’s pricing could yield significant savings for seven generic oncology drugs vs. Medicare Part D median formulary prices, according to study results published in Journal of Clinical Oncology.

Medicare Advantage enrollees with mildly reduced kidney function and accelerated eGFR decline have disproportionately higher medical costs than other patients, data show.

Recent recommendations from MedPAC regarding Medicare Part B physician reimbursements will “do nothing to address the root cause” of high drug prices, according to Madelaine A. Feldman, MD, FACR.

The American College of Rheumatology is sounding the alarm over a recent recommendation from the Medicare Payment Advisory Commission — or MedPAC — that it says would cut physician reimbursements for infused therapies.

Results showed older, Black and female patients have been less likely to undergo outpatient total knee replacement after the removal of TKR from the Medicare inpatient-only list in 2018.

The American Academy of Neurology has submitted a formal national coverage determination reconsideration request to CMS regarding current coverage of amyloid-targeting monoclonal antibodies for Alzheimer’s disease, including Leqembi.

HHS has released a list of 43 prescription drugs for which Part B beneficiary coinsurances may be lower starting July 1.

Legislators have introduced a bill to restore cuts in Medicare funding for office-based procedures, including for vascular access.

Medicare will cover drugs that may slow the progression of Alzheimer’s disease if granted traditional approval from the FDA, according to a press release from CMS.